[Treatment concepts for primary oligometastatic prostate cancer]. / Therapiekonzepte beim primär oligometastasierten Prostatakarzinom.
Urologe A
; 59(6): 659-664, 2020 Jun.
Article
en De
| MEDLINE
| ID: mdl-32274541
ABSTRACT
BACKGROUND:
About 5% of prostate cancer patients have distant metastases at diagnosis. In these metastatic hormone-sensitive prostate cancers (mHSPC), systemic therapy is recommended, according to the guidelines. Moreover, metastasis-directed therapy (MDT) is discussed to prolong survival.OBJECTIVES:
The contemporary literature concerning local therapy and MDT in patients with mHSPC is summarized.METHODS:
Selective literature search.RESULTS:
In 2018, randomized controlled data on local therapy in mHSPC patients were published by the authors of the STAMPEDE study. Here, patients were randomized between standard of care (SOC)⯱ radiotherapy to the prostate (RT). Within the overall cohort, no difference regarding 3year overall survival (OS) was observed. Within a prespecified subgroup of patients with low metastatic burden. Similar results were observed in numerous retrospective studies analyzing radical prostatectomy; prospective randomized studies are pending. For MDT, there are no sufficient data in mHSPC patients yet.CONCLUSIONS:
In the current guidelines, systematic therapy is standard of care in mHSPC patients. In patients with low metastatic burden, a survival benefit was observed when adding percutaneous RT to the prostate. Retrospective studies also suggest a benefit when adding RP. However, whether MDT prolongs survival is still unknown.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Prostatectomía
/
Neoplasias de la Próstata
/
Antineoplásicos Hormonales
Tipo de estudio:
Clinical_trials
/
Guideline
/
Observational_studies
Límite:
Humans
/
Male
Idioma:
De
Revista:
Urologe A
Año:
2020
Tipo del documento:
Article